Blog - Page 2 of 5632 - QualityStocks

FridayMay 15, 2026 12:17 pm

QualityStocksNewsBreaks – Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Arctic Project Receives FAST-41 Covered Project Designation

This article has been disseminated on behalf of Trilogy Metals Inc. and may include paid advertising. Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) announced that its flagship Arctic Project in Alaska, being advanced through its 50/50 Ambler Metals joint venture with South32, has been accepted as a FAST-41 Covered Project on the Federal Permitting Dashboard, a designation intended to streamline and coordinate federal environmental review and permitting timelines for major infrastructure and critical mineral projects. The milestone follows Ambler Metals’ recent Clean Water Act permit application filing and positions the Arctic Project as a priority domestic critical minerals development initiative, providing a defined federal permitting…

FridayMay 15, 2026 12:05 pm

QualityStocksNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Featured in NetworkNewsAudio Editorial on Voice-Based Intoxication Detection

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) was featured in a NetworkNewsAudio audio press release highlighting the emerging potential of AI-powered voice analysis as a noninvasive method for intoxication detection. The editorial explores how speech-based diagnostics may offer rapid, real-time assessment of cognitive and physiological impairment by analyzing measurable vocal biomarkers such as tone, pitch, rhythm and articulation. To view the full press release, visit https://ibn.fm/uaVeg About MindBio Therapeutics Corp. MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to…

FridayMay 15, 2026 11:55 am

QualityStocksNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Poised at Intersection of Precision Medicine, Preventive Care

Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision medicine company leveraging epigenetics, genetics and artificial intelligence, is poised to meet demands as cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide. “Cardio Diagnostics is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic biomarkers to deliver personalized cardiovascular insights from a simple blood sample, positioning itself at the intersection of precision medicine and preventive care,” reads a recent article. “Cardio Diagnostics is addressing this need through its proprietary platform, which combines artificial intelligence with multi-omic biomarker analysis. The…

FridayMay 15, 2026 11:53 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on CNS Drug Delivery Innovation

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a NetworkNewsAudio audio press release focused on emerging opportunities in central nervous system drug delivery, highlighting the challenges posed by the blood-brain barrier and the company’s efforts to advance technologies designed to overcome those limitations. The editorial also noted Oncotelic’s recent strategic monetization agreement with Lunai Bioworks involving its N2B delivery system, supporting initiatives in biodefense and Alzheimer’s disease treatment. To view the full press release, visit https://ibn.fm/Mjhjw About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic…

FridayMay 15, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Offers Broad Suite of AI-Powered Solutions for Cardiovascular Disease Prevention

Research supports the urgent need for more effective tools to identify the risk of cardiovascular disease earlier and guide personalized intervention strategies. Cardio Diagnostics’ solutions reflect a strategy aimed at addressing cardiovascular disease across multiple stages of care. This emphasis on prevention aligns with growing recognition that earlier intervention can significantly improve long-term outcomes. Most people are aware that cardiovascular disease (“CVD”) is the leading cause of death in the United States; what they might not know is that an estimated 80% of those cases are considered preventable through earlier detection and proactive management of key risk factors. This highlights…

FridayMay 15, 2026 10:40 am

QualityStocksNewsBreaks – SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Featured in NetworkNewsAudio Editorial on Autonomous Drone Software

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) was featured in a NetworkNewsAudio audio press release focused on the evolving role of software in next-generation drone warfare, highlighting the increasing importance of autonomy, target identification and resilience in contested electronic warfare environments. The editorial spotlighted the company’s Overwatch platform as a software-driven solution designed to address operational limitations of mass-produced drone hardware. To view the full press release, visit https://ibn.fm/xojlI About SPARC AI Inc. SPARC AI is a defence technology company solving one of…

FridayMay 15, 2026 10:30 am

QualityStocksNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in NetworkNewsAudio Editorial on Next-Generation GLP-1 Therapies

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) was featured in a NetworkNewsAudio audio press release examining the evolution of the GLP-1 treatment market, highlighting the company’s development of GEP-44, a patented next-generation metabolic therapy designed to improve on first-generation GLP-1 drugs. The editorial noted GEP-44’s triple agonist mechanism targeting GLP-1 and peptide YY receptors, with preclinical data indicating potential benefits in appetite suppression, weight reduction and glycemic control with improved tolerability. To view the full press release, visit https://ibn.fm/wsiDy About SureNano Science Ltd. SureNano Science Ltd. (CSE:…

FridayMay 15, 2026 10:30 am

Frontieras North America Inc.’s Game-Changing Tech ‘Unlocks’ Coal as Multi-Output Industrial Feedstock

The company’s proprietary FASForm(TM) platform advancing new approach to coal. Frontieras processes coal into multiple commercially valuable outputs, tied to markets estimated at more than $2 trillion. Core thesis is that coal’s largest missed opportunity lies not in power generation alone but in its unrealized value as a diversified industrial resource. Global demand for energy is accelerating at a historic pace as artificial intelligence (“AI”), advanced manufacturing and industrial expansion place increasing pressure on existing power systems. Governments and industries are exploring nearly every available energy source to meet that demand, yet one of the world’s most abundant and energy-dense…

FridayMay 15, 2026 10:20 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports First-Quarter Results, Highlights Progress Across Biotech Platform

Oncotelic Therapeutics (OTCQB: OTLC) reported first-quarter 2026 financial results and a corporate update highlighting continued advancement across its oncology, AI-enabled drug development and advanced drug delivery initiatives, including progress within its Sapu Nano joint venture and nose-to-brain CNS delivery platform. The company also said it maintained the previously established approximately $388 million fair value of its 45% ownership interest in GMP Biotechnology as of March 31, 2026, while continuing to pursue capital-efficient growth across its diversified biotechnology platform. To view the full press release, visit https://ibn.fm/DTVsF About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the…

FridayMay 15, 2026 9:50 am

QualityStocksNewsBreaks – SOLOWIN HOLDINGS (NASDAQ: AXG) Subsidiary AX Coin Partners With INFINIOS on Stablecoin Payment Infrastructure

SOLOWIN HOLDINGS (NASDAQ: AXG) announced that its AX Coin stablecoin subsidiary has signed a non-binding memorandum of understanding with INFINIOS to develop regulated wallet infrastructure and digital payment solutions aimed at accelerating stablecoin adoption across the Gulf region. The collaboration is expected to integrate AX Coin into INFINIOS’ payments infrastructure, enabling compliant custodial and non-custodial wallet solutions, multi-currency virtual accounts, fiat on/off ramps, and real-time cross-border settlement capabilities for institutional clients. To view the full press release, visit https://ibn.fm/Hpyle About SOLOWIN HOLDINGS SOLOWIN HOLDINGS (Nasdaq: AXG) is a leading global regulated fintech company. Established in 2016, AXG combines blockchain and…

Site Search

Company Search